Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.63 |
| ▸ | LIPE | Q05469 | 11/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785431 | 1.00 | GPR119 (0.63) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL30036700 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL30036877 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL30037279 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL26620505 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL23702967 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL7956617 | 0.93 | HSD11B1 (0.61) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL31312638 | 0.88 | LIPE (0.51) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL30329049 | 0.86 | GPR119 (0.48) | GPR119LIPEHSD11B1LIPG | |
| SCHEMBL2775443 | 0.86 | GPR119 (0.66) | GPR119LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-111004218-B | Pyrimidine compound containing piperidine and application thereof | 沈阳中化农药化工研发有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022130352-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-111004218-A | Piperidine-containing pyrimidine compound and application thereof | 沈阳中化农药化工研发有限公司 | 2020-04-14 | — | — | CN | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1347990-A2 | PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002055541-A2 | PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-18 | — | — | WO | disclosed |
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GPR119 1166/4885LIPE 2450/4885HSD11B1 4209/4885 |
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | GPR119 118/4885LIPE 2037/4885HSD11B1 190/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | GPR119 101/4885LIPE 250/4885HSD11B1 2761/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | GPR119 1947/4885LIPE 3425/4885HSD11B1 2992/4885 |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | GPR119 1336/4885LIPE 4566/4885HSD11B1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.